Beatriz García-Paredes

414 total citations
18 papers, 250 citations indexed

About

Beatriz García-Paredes is a scholar working on Oncology, Surgery and Hepatology. According to data from OpenAlex, Beatriz García-Paredes has authored 18 papers receiving a total of 250 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Surgery and 5 papers in Hepatology. Recurrent topics in Beatriz García-Paredes's work include Colorectal Cancer Treatments and Studies (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Genetic factors in colorectal cancer (4 papers). Beatriz García-Paredes is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Genetic factors in colorectal cancer (4 papers). Beatriz García-Paredes collaborates with scholars based in Spain, France and Denmark. Beatriz García-Paredes's co-authors include Enrique Aranda, Eduardo Díaz‐Rubio, Cristina Grávalos, Fernando Rivera, María José Safont, Carles Pericay, Encarnación González‐Flores, Alfredo Carrato, Javier Sastre and Pilar García‐Alfonso and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Beatriz García-Paredes

17 papers receiving 246 citations

Peers

Beatriz García-Paredes

ONCOL

PRM

PFM

SURGE

Giuliana D’Auria Italy

Chloé Broudin France

A. Fittipaldo United Kingdom

Jiewen Peng China

F. Losa Gaspà Spain

C. Zingaretti Italy

Mostefa Bennamoun France

S.-B. Kim South Korea

Erienne M.V. de Cuba Netherlands

Trevor Feinstein United States

Giuliana D’Auria Italy

Beatriz García-Paredes

164 ×0.9

ONCOL

119 ×1.8

PRM

12 ×0.2

PFM

21 ×0.4

SURGE

Citations per year, relative to Beatriz García-Paredes Beatriz García-Paredes (= 1×) peers Giuliana D’Auria

Countries citing papers authored by Beatriz García-Paredes

Since Specialization

Citations

This map shows the geographic impact of Beatriz García-Paredes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatriz García-Paredes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatriz García-Paredes more than expected).

Fields of papers citing papers by Beatriz García-Paredes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beatriz García-Paredes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatriz García-Paredes. The network helps show where Beatriz García-Paredes may publish in the future.

Co-authorship network of co-authors of Beatriz García-Paredes

This figure shows the co-authorship network connecting the top 25 collaborators of Beatriz García-Paredes. A scholar is included among the top collaborators of Beatriz García-Paredes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beatriz García-Paredes. Beatriz García-Paredes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

López, Carlos, Mariona Calvo, Juan Carlos Cámara, et al.. (2024). SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). Clinical & Translational Oncology. 26(11). 2800–2811. 2 indexed citations

Jiménez‐Fonseca, Paula, Javier Sastre, Pilar García‐Alfonso, et al.. (2023). Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials. Clinical Colorectal Cancer. 22(2). 222–230. 3 indexed citations

Aranda, Enrique, José María Viéitez, Auxiliadora Gómez‐España, et al.. (2020). FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial. ESMO Open. 5(6). e000944–e000944. 39 indexed citations

Montés, Ana Fernández, Cristina Grávalos, Carles Pericay, et al.. (2020). Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. Clinical Colorectal Cancer. 19(3). 165–177. 18 indexed citations

Salazar, Ramón, Jaume Capdevila, José Luís Zamora Manzano, et al.. (2020). Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. BMC Cancer. 20(1). 1164–1164. 9 indexed citations

Ducreux, Michel, Lone Nørgård Pétersen, Leopold Öhler, et al.. (2019). Outcomes by tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): Final analysis from the prospective, observational CORRELATE study.. Journal of Clinical Oncology. 37(4_suppl). 539–539. 2 indexed citations

Martín, Miguel, Sara López‐Tarruella, Antonio Casado, et al.. (2018). Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Research and Treatment. 171(3). 627–634. 30 indexed citations

Viéitez, José María, Silvia Gil, Begoña Graña, et al.. (2018). Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).. Journal of Clinical Oncology. 36(15_suppl). 3536–3536. 2 indexed citations

Martín, Andrés J. Muñoz, Carles Pericay, Ana Ruiz‐Casado, et al.. (2018). Metastases resection after FOLFIRI-aflibercept (FA) in oxaliplatin-refractory colorectal cancer patients (ORF-CRC).. Journal of Clinical Oncology. 36(4_suppl). 862–862. 2 indexed citations

10.

Montés, Ana Fernández, Alberto Carmona‐Bayonas, David Páez, et al.. (2017). Efficacy and toxicity results of FOLFIRI-Aflibercept in advanced colorectal cancer (CRCm) in “real life”, retrospective study. Prognostic factors and specific populations.. Annals of Oncology. 28. iii103–iii103. 3 indexed citations

11.

Carrato, Alfredo, Albert Abad, Bartomeu Massutí, et al.. (2017). First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). European Journal of Cancer. 81. 191–202. 62 indexed citations

12.

Rueda, Daniel, Carmen Povés, María Jesús Fernández‐Aceñero, et al.. (2017). Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome. PLoS ONE. 12(11). e0187312–e0187312. 8 indexed citations

13.

Pericay, Carles, Nieves Martínez Lago, Ismael Macías, et al.. (2016). P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA). Annals of Oncology. 27. ii15–ii15. 1 indexed citations

14.

Fernández‐Aceñero, María Jesús, et al.. (2016). Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 468(4). 425–430. 14 indexed citations

15.

Mesı́a, Ricard, Silvia Vázquez, Juan J. Grau, et al.. (2015). A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 94(2). 289–296. 22 indexed citations

16.

Sastre, Javier, Cristina Fernández, C. Ramírez, et al.. (2015). Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine–Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series. Clinical Colorectal Cancer. 15(2). 128–134. 3 indexed citations

17.

Aranda, Enrique, Pilar García‐Alfonso, Manuel Benavides, et al.. (2015). 2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial. European Journal of Cancer. 51. S371–S372.

18.

Garré, Pilar, Atocha Romero, Alicia Tosar, et al.. (2014). BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X. Clinical Genetics. 87(6). 582–587. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact